Termination of Pregnancy With Mifepristone and Misoprostol Versus Sulprostone

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Atrium Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Atrium Medical Center
ClinicalTrials.gov Identifier:
NCT00206193
First received: September 13, 2005
Last updated: October 29, 2007
Last verified: September 2005
  Purpose

The purpose of this study is to determine which medical treatment is the most effective to terminate a pregnancy.


Condition Intervention Phase
Abortion, Induced
Drug: mifepristone
Drug: misoprostol
Drug: sulprostone
Phase 2

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Atrium Medical Center:

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Criteria

Inclusion Criteria:

  • Pregnant women by whom a termination of pregnancy is desired.

Exclusion Criteria:

  • Women with liver/kidney disease
  • Women on long-term use of corticosteroids (> 6 months)
  • Cardiovascular problems
  • Therapy-resistant diabetic women
  • Therapy-resistant asthma/bronchitis
  • Thalassemia
  • Ulcerative colitis
  • Peptic ulcer disease
  • Glaucoma
  • Porphyria
  • Allergic reaction to prostaglandin or mifepristone
  • Women with a prior caesarian section or women with contractions at the start of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00206193

Contacts
Contact: Suzanne HW Vonken, Dr. 003145-5766666 ext 466825 svonken@gmail.com
Contact: F Roumen, Dr. 003145-5766666 ext 466509

Locations
Netherlands
Atrium Medisch Centrum Recruiting
Heerlen, Limburg, Netherlands
Contact: Suzanne HW Vonken, Dr.    045-5766666(6825)      
Principal Investigator: Suzanne HW Vonken, Dr.         
Sponsors and Collaborators
Atrium Medical Center
Investigators
Study Director: F Roumen, Dr. Atrium Medisch Centrum, Heerlen
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00206193     History of Changes
Other Study ID Numbers: TOP-protocol
Study First Received: September 13, 2005
Last Updated: October 29, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Atrium Medical Center:
termination of pregnancy

Additional relevant MeSH terms:
Misoprostol
Sulprostone
Mifepristone
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Anti-Ulcer Agents
Gastrointestinal Agents
Oxytocics
Abortifacient Agents, Steroidal
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Contraceptives, Postcoital, Synthetic
Contraceptives, Postcoital
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents

ClinicalTrials.gov processed this record on September 16, 2014